 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII |
|
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C10H15N3O |
| Molar mass | 193.250 g·mol |
| 3D model (JSmol) | |
SMILES
| |
Sabcomeline (Memric; SB-202,026) is a selective M1 receptor partial agonist that was under development for the treatment of Alzheimer's disease. It made it to phase III clinical trials before being discontinued due to poor results.
It is a non-selective agonist of all five muscarinic acetylcholine receptors with similar affinities. However, functional selectivity for the M1 receptor has been claimed in vitro and in vivo.
See also
References
- Loudon JM, Bromidge SM, Brown F, et al. (December 1997). "SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors". The Journal of Pharmacology and Experimental Therapeutics. 283 (3): 1059–68. PMID 9399977.
- ^ Wood MD, Murkitt KL, Ho M, Watson JM, Brown F, Hunter AJ, Middlemiss DN (April 1999). "Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry". Br J Pharmacol. 126 (7): 1620–1624. doi:10.1038/sj.bjp.0702463. PMC 1565933. PMID 10323594.
| Psychoanaleptics: Anti-dementia agents (ATC code N06D and others) | |
|---|---|
| AChE inhibitor medications | |
| Other medications | |
| Experimental BACE inhibitors | |